Arkopharma Executes Plan to Revive Growth

After two years of declining revenues and margins, the publicly held, family run French supplement marketer Arkopharma Group, is honing its strategy to recover from its losses and renew the strong growth track it has been on for most of the last decade. The company’s plan—much of which is already underway—includes reducing its product portfolio by 30%, shedding or restructuring money-losing U.S. and German subsidiaries, cutting overhead and personnel and keeping a lid on investments,

All access premium subscription

This content requires a subscription to Nutrition Business Journal.

As an NBJ subscriber, you receive 10 issues a year and access to the exclusive “NBJ subscriber only” content on newhope.com (excludes three-month subscriptions), which includes PowerPoint presentations, select data charts and archived articles. Subscribers also receive a 10 percent discount on data charts, comprehensive market research reports and webinars.

Email [email protected] for more information about subscribing.